alpha-synuclein


Also found in: Medical, Wikipedia.

al·pha-sy·nu·cle·in

 (ăl′fə-sĭ-no͞o′klē-ĭn, -nyo͞o′-)
n.
A polypeptide protein found primarily in brain neurons but seen also in the fibrils in Parkinson's disease, in the amyloid plaques of Alzheimer's disease, and in brain tissue affected by other neurodegenerative diseases.
References in periodicals archive ?
The biomarker was found to be significantly elevated in the skin samples of Alzheimer's and Parkinson's patients; alpha-synuclein protein was also found to be elevated in the samples of Parkinson's patients.
The SNCA gene codes for making the alpha-synuclein protein, which is found within neurons at presynaptic nerves and in other cell types.
The assay is based on CSF measurements of toxic oligomer/protofibril forms of alpha-synuclein.
Patients with Parkinson's disease also showed a similarly increased expression of alpha-synuclein, the investigators found.
But a few other substances -- a vaccine against a protein called alpha-synuclein, a blood pressure drug called isradipine, and inosine, a supplement that raises urate levels -- are showing promise in clinical trials.
The vaccine was developed by the Austrian biotech company AFFiRiS AG and targets a protein called alpha-Synuclein.
One of the most promising is a blood test for raised levels of the protein alpha-synuclein.
Austria-based Affiris AG (AG), a developer of tailor-made drugs mainly as Peptide-based vaccines, has announced that an initial therapy against the protein alpha-synuclein, a promising Parkinson's drug target, will enter clinical testing.
Some of the newly identified genetic risk factors are thought to be involved with Gaucher's disease, regulating inflammation and the nerve cell chemical messenger dopamine as well as alpha-synuclein, a protein that has been shown to accumulate in the brains of some cases of Parkinson's disease.
Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
The vaccine targets the protein alpha-Synuclein, which is responsible for the onset of the disease.
Their models produce cognitive impairment, as assessed in the Morris Water Maze, and increase expression of tau, p-tau, APP, A[sz] and alpha-synuclein in the brain.